阿拉丁小分子抑制剂、激动剂、拮抗剂--血管生成信号通路（下）

血管生成

血管生成，即从已存在的血管中生成新血管。此通路是通过人体中存在的诸多互补和复杂的信号途径调节的。正常情况下，血管生成的相关诱导剂和抑制剂之间保持平衡状态。但对于创伤、缺氧或炎症继发等微环境破坏的条件下，此通路能做出迅速的应答。在各种慢性病理和肿瘤的情况下，血管生成的平衡状态被打破，导致异常的血管生成或新生血管。

血管生成信号通路转导过程

血管生成的激活导致促血管生成生长因子（VEGF、PDGF、FGF和TGF等）的释放，这些因子将其受体结合到已有血管内的内皮细胞上，从而诱导PI3K/Akt、Erk1/2、Smad和Notch等多种途径的信号转导，引起内皮细胞增殖和迁移。内皮细胞利用基质金属蛋白酶和整合素来消化细胞外基质，迁移到新的区域，在那里它们延长并形成管子，产生新的血管。
在肿瘤血管生成过程中，癌细胞刺激新血管的形成，为肿瘤输送氧气和营养。随着肿瘤的生长，位于肿瘤中心的细胞缺氧，使得转录因子HIF-1α（缺氧诱导因子-1）稳定表达。该转录因子与HIF-1β结合上调几种促血管生成基因的表达。此外，生长因子信号还刺激HIF-1活性，以维持生长细胞的氧稳态。

血管生成信号通路图

产品列表

? ?*JAK

项目号	产品名称	规格	CAS	包装	细胞	靶点	IC50	Ki	EC50
R126338	Ruxolitinib (INCB018424)	≥98%	941678-49-5	5mg,25mg,50mg,100mg	无细胞	JAK1	3.3 nM
R126338	Ruxolitinib (INCB018424)	≥98%	941678-49-5	5mg,25mg,50mg,100mg	无细胞	JAK2	2.8 nM
E129454	Tofacitinib (CP-690550) Citrate	≥99%	540737-29-9	10mg,50mg,250mg		JAK1	112 nM
						JAK2	20 nM
						JAK3	1 nM
A126326	AZD1480	≥98%	935666-88-9	5mg,25mg,100mg	无细胞	JAK2	0.26 nM
T126330	Fedratinib (SAR302503, TG101348)	≥98%	936091-26-8	5mg,25mg,100mg	无细胞	JAK2	3 nM
J126663	JANEX-1	98%	202475-60-3	5mg,10mg,50mg	?	JAK3	78 μM
W125855	WHI-P97	≥98%	211555-05-4	10mg,50mg		JAK-3		0.09 μM
C127224	CYT387	≥98%	1056634-68-4	5mg,10mg,50mg,100mg		JAK1	11 nM
C127224	CYT387	≥98%	1056634-68-4	5mg,10mg,50mg,100mg		JAK2	18 nM
T122330	Tofacitinib	≥98% (HPLC)	477600-75-2	5mg,25mg,100mg,500mg,1g	无细胞	JAK3	1 nM
W129459	WP1066	≥98%	857064-38-1	10mg,50mg	HEL细胞	JAK2	2.30 μM
W129459	WP1066	≥98%	857064-38-1	10mg,50mg	HEL细胞	STAT3	2.43 μM
T127523	TG101209	98%	936091-14-4	5mg,25mg,100mg	无细胞	JAK2	6 nM
						Flt3	25 nM
						RET	17 nM
L126490	LY2784544	≥98%	1229236-86-5	5mg,10mg,50mg	?	JAK2	3 nM
N129609	NVP-BSK805 2HCl	≥97%	1092499-93-8	5mg,10mg,50mg	?	JAK2	0.5 nM
B127687	Baricitinib	≥99%	1187594-09-7	5mg,10mg,50mg	无细胞	JAK1	5.9 nM
B127687	Baricitinib	≥99%	1187594-09-7	5mg,10mg,50mg	无细胞	JAK2	5.7 nM
A129464	AZ 960	≥99%	905586-69-8	2mg,5mg,10mg	?	JAK2	＜3 nM	＜0.45 nM
C129474	CEP-33779	≥99%	1257704-57-6	5mg,10mg,50mg	?	JAK2	1.8 nM
W125072	WHI-P154	≥98%	211555-04-3	10mg,50mg		JAK3	1.8 μM
X127151	XL019	≥99%	945755-56-6?	5mg,25mg		JAK2	2.2 nM
S129613	S-Ruxolitinib (INCB018424)	≥99%	941685-37-6	5mg,10mg,50mg		JAK1	3.3 nM
S129613	S-Ruxolitinib (INCB018424)	≥99%	941685-37-6	5mg,10mg,50mg		JAK2	2.8 nM
Z129618	ZM 39923 HCl	≥98%	1021868-92-7	10mg,50mg,250mg		JAK1			4.4
Z129618	ZM 39923 HCl	≥98%	1021868-92-7	10mg,50mg,250mg		JAK3			7.1
R171967	Ruxolitinib phosphate salt	97%	1092939-17-7	100mg		JAK
C114054	莪术醇	分析标准品,≥98%	4871-97-0	20mg

?*EGFR

项目号	产品名称	规格	CAS	包装	细胞	靶点	IC50	Ki
L126696	Lapatinib	≥99%	231277-92-2	25mg,100mg,250mg,500mg,1g,5g		ErbB2	9.2 nM
L126696	Lapatinib	≥99%	231277-92-2	25mg,100mg,250mg,500mg,1g,5g		EGFR	10.8 nM
L193141	二甲苯磺酸拉帕替尼一水合物	0.98	388082-78-8	1g,5g		EGFR	10.8 nM
L193141	二甲苯磺酸拉帕替尼一水合物	0.98	388082-78-8	1g,5g		ErbB2	9.2 nM
E129310	Erlotinib HCl (OSI-744)	≥99%	183319-69-9	100mg,500mg,1g,5g	无细胞	EGFR	2 nM
G125799	Gefitinib (ZD1839)	≥99%	184475-35-2	50mg,250mg,1g,5g,25g,100g	NR6wtEGFR	Tyr1173	37 nM
					NR6wtEGFR	Tyr992	37nM
					NR6W	Tyr1173	26 nM
					NR6W	Tyr992	57 nM
L129338	二对甲苯磺酸拉帕替尼(GW-572016)	≥98%	388082-77-7	25mg,100mg,250mg,500mg,1g	无细胞	ErbB2	9.2 nM
L129338	二对甲苯磺酸拉帕替尼(GW-572016)	≥98%	388082-77-7	25mg,100mg,250mg,500mg,1g	无细胞	EGFR	10.8 nM
V125180	Vandetanib (ZD6474)	≥99%	443913-73-3	25mg,100mg,500mg	无细胞	VEGFR2	40 nM
						VEGFR3	110 nM
						EGFR	500 nM
N126132	Neratinib (HKI-272)	≥99%	698387-09-6	5mg,25mg,100mg	无细胞	ER2	59 nM
N126132	Neratinib (HKI-272)	≥99%	698387-09-6	5mg,25mg,100mg	无细胞	EGFR	92 nM
C125447	Canertinib (CI-1033)	≥98%	267243-28-7	10mg,50mg,250mg		EGFR	1.5 nM
C125447	Canertinib (CI-1033)	≥98%	267243-28-7	10mg,50mg,250mg		ErbB2	9.0 nM
A126525	AG-490 (Tyrphostin B42)	≥98%	133550-30-8	20mg,50mg,250mg,1g	无细胞	EGFR	0.1 μM
C129397	CP-724714	≥99%	537705-08-1	5mg,10mg,25mg,50mg	?	HER2/ErbB2	10 nM
D129347	Dacomitinib (PF299804, PF299)	≥99%	1110813-31-4	5mg,10mg,50mg,250mg	?	EGFR	6 nM
W127713	WZ4002	≥98%	1213269-23-8	10mg,50mg,100mg	BaF3细胞系	EGFR(L858R)	2 nM
W127713	WZ4002	≥98%	1213269-23-8	10mg,50mg,100mg	BaF3细胞系	EGFR(T790M)	8 nM
A129380	AZD8931 (Sapitinib)	≥98%	848942-61-0	5mg,10mg,50mg	无细胞	EGFR	4 nM
						ErbB2	3 nM
						ErbB3	4 nM
C127191	CUDC-101	≥98%	1012054-59-9	10mg,25mg,50mg,100mg,250mg		HDAC	4.4 nM
						EGFR	2.4 nM
						HER2	15.7 nM
A126582	AG-1478 (Tyrphostin AG-1478)	≥98%	153436-53-4	5mg,10mg,25mg,50mg	无细胞	EGFR	3 nM
P129384	PD153035 HCl	≥98%(HPLC)	183322-45-4	10mg,50mg,250mg	无细胞	EGFR	29 pM	5.2 pM
P125444	Pelitinib	≥98%	257933-82-7	5mg,25mg,100mg		EGFR	3.5 nM
						Src	282 nM
						MEK/ERK	800 nM
						ErbB2	1255 nM
B126145	AC480 (BMS-599626)	≥98%	714971-09-2	5mg,10mg,25mg,100mg		HER1	20 nM
B126145	AC480 (BMS-599626)	≥98%	714971-09-2	5mg,10mg,25mg,100mg		HER2	30 nM
A126830	AEE788 (NVP-AEE788)	≥97%	497839-62-0	5mg,25mg,100mg		EGFR	2 nM
A126830	AEE788 (NVP-AEE788)	≥97%	497839-62-0	5mg,25mg,100mg		HER2/ErbB2	6 nM
A127691	AP26113	≥98%	1197958-12-5	5mg,10mg,25mg,		ALK
A127691	AP26113	≥98%	1197958-12-5	5mg,10mg,25mg,		EGFR
O125033	OSI-420	≥99%	183320-51-6	1mg,5mg,10mg,50mg	?	EGFR	2 nM
W127717	WZ3146	≥98%	1214265-56-1	1mg,5mg,25mg,100mg		EGFR(L858R)	2 nM
W127717	WZ3146	≥98%	1214265-56-1	1mg,5mg,25mg,100mg		EGFR(E746_A750)	2 nM
A126334	ARRY-380	≥98%	937265-83-3	1mg,5mg,10mg,50mg	?	HER2	8 nM
W126471	WZ8040	≥98%	1214265-57-2	1mg,5mg,25mg,50mg	?	EGFR
A129426	AST-1306 TsOH	≥98%	1050500-29-2	5mg,10mg,50mg		EGFR	0.5 nM
A129426	AST-1306 TsOH	≥98%	1050500-29-2	5mg,10mg,50mg		ErbB2	3 nM
C124905	CO-1686 (AVL-301)	≥99%	1374640-70-6	5mg,10mg,50mg,100mg	无细胞	EGFRL858R/T790M		21.5 nM
C124905	CO-1686 (AVL-301)	≥99%	1374640-70-6	5mg,10mg,50mg,100mg	无细胞	EGFRWT		303.3 nM
G106672	金雀异黄酮	分析标准品,≥98%	446-72-0	20mg,1g,5g	NIH-3T3细胞	EGF	12μM
G106672	金雀异黄酮	分析标准品,≥98%	446-72-0	20mg,1g,5g	NIH-3T3细胞	胰岛素	19 μM
G106673	金雀异黄酮	97%	446-72-0	100mg,500mg,1g,5g,25g	NIH-3T3细胞	EGF	12μM
G106673	金雀异黄酮	97%	446-72-0	100mg,500mg,1g,5g,25g	NIH-3T3细胞	胰岛素	19 μM
V129433	Varlitinib	≥96%	845272-21-1	1mg,5mg,10mg,50mg		ErbB1(EGFR)	7 nM
V129433	Varlitinib	≥96%	845272-21-1	1mg,5mg,10mg,50mg		ErbB2(HER2)	2 nM
I129405	Icotinib	≥99%	610798-31-7	5mg,10mg,50mg	?	EGFR	5 nM
T126234	TAK-285	≥98%	871026-44-7	1mg,5mg,10mg,50mg		HER2	17 nM
T126234	TAK-285	≥98%	871026-44-7	1mg,5mg,10mg,50mg		EGFR(HER1)	23 nM
W125072	WHI-P154	≥98%	211555-04-3	10mg,50mg		JAK3	1.8 μM
D155111	Daphnetin	>90.0%(HPLC)	486-35-1	50mg,100mg,250mg,1g		EGFR	7.67 μM
						PKA	9.33 μM
						PKC	25.01 μM
P129447	PD168393	≥98%	194423-15-9	10mg,50mg,250mg	?	EGFR	0.70 nM
T129439	Tyrphostin 9	≥98%	10537-47-0	25mg,50mg,100mg,500mg		EGFR	460 μM
T129439	Tyrphostin 9	≥98%	10537-47-0	25mg,50mg,100mg,500mg		PDGFR	0.5μM
T129445	Tyrphostin 23	≥98%	118409-57-7	10mg,50mg,250mg	?	EGFR	35 μM
T162509	酪氨酸激酶抑制剂 AG 494	>98.0%(HPLC)(N)	133550-35-3	20mg,100mg		EGFR	1.2 μM
T162509	酪氨酸激酶抑制剂 AG 494	>98.0%(HPLC)(N)	133550-35-3	20mg,100mg		EGF	6 μM
O173511	Olmutinib	97%	1353550-13-6	5mg,100mg
PD153035	PD153035	≥98%	153436-54-5	10mg,50mg,250mg	?	EGFR		5.2 pM
E126691	EBE-A22	-	229476-53-3	5mg,10mg,25mg,50mg,100mg	?	?
E107404	(-)-表没食子儿茶素没食子酸	98%	989-51-5	100mg,200mg,2.5g	?	EGF/HER-2
E107403	(-)-表没食子儿茶素没食子酸	分析标准品	989-51-5	20mg,100mg		EGF/HER-2
E126633	Erlotinib	≥98%	183321-74-6	100mg,500mg,1g,5g	?	EGFR	2 nM
D101144	大黄酚	97%	481-74-3	50mg,250mg,1g		EGFR
D101144	大黄酚	97%	481-74-3	50mg,250mg,1g		mTOR
D101143	大黄酚	分析标准品,≥98%	481-74-3	20mg		EGFR
D101143	大黄酚	分析标准品,≥98%	481-74-3	20mg		mTOR
N159736	Norcantharidin	98%	29745-04-8	1g,5g,25g		c-Met
N159736	Norcantharidin	98%	29745-04-8	1g,5g,25g		EGFR
B135922	Butein	≥98.0%(HPLC)	487-52-5	100mg,1g		EGFR

*HER2

项目号	产品名称	规格	CAS	包装	细胞	靶点	IC50
L129338	二对甲苯磺酸拉帕替尼(GW-572016)	≥98%	388082-77-7	25mg,100mg,250mg,500mg,1g	无细胞	ErbB2	9.2 nM
L129338	二对甲苯磺酸拉帕替尼(GW-572016)	≥98%	388082-77-7	25mg,100mg,250mg,500mg,1g	无细胞	EGFR	10.8 nM
N126132	Neratinib (HKI-272)	≥99%	698387-09-6	5mg,25mg,100mg	无细胞	HER2	59 nM
N126132	Neratinib (HKI-272)	≥99%	698387-09-6	5mg,25mg,100mg	无细胞	EGFR	92 nM
C125447	Canertinib (CI-1033)	≥98%	267243-28-7	10mg,50mg,250mg		EGFR	1.5 nM
C125447	Canertinib (CI-1033)	≥98%	267243-28-7	10mg,50mg,250mg		ErbB2	9.0 nM
L126696	Lapatinib	≥99%	231277-92-2	25mg,100mg,250mg,500mg,1g,5g		ErbB2	9.2 nM
L126696	Lapatinib	≥99%	231277-92-2	25mg,100mg,250mg,500mg,1g,5g		EGFR	10.8 nM
C129397	CP-724714	≥99%	537705-08-1	5mg,10mg,25mg,50mg	?	HER2/ErbB2	10 nM
D129347	Dacomitinib (PF299804, PF299)	≥99%	1110813-31-4	5mg,10mg,50mg,250mg	?	EGFR	6 nM
A129380	AZD8931 (Sapitinib)	≥98%	848942-61-0	5mg,10mg,50mg	无细胞	EGFR	4 nM
						ErbB2	3 nM
						ErbB3	4 nM
C127191	CUDC-101	≥98%	1012054-59-9	10mg,25mg,50mg,10mmg,250mg		HDAC	4.4 nM
						EGFR	2.4 nM
						HER2	15.7 nM
M129797	Mubritinib (TAK 165)	≥99%	366017-09-6	10mg,50mg,250mg	T-474细胞	HER2/ErbB2	6 nM
B126145	AC480 (BMS-599626)	≥98%	714971-09-2	5mg,10mg,25mg,100mg		HER1	20 nM
B126145	AC480 (BMS-599626)	≥98%	714971-09-2	5mg,10mg,25mg,100mg		HER2	30 nM
A126830	AEE788 (NVP-AEE788)	≥97%	497839-62-0	5mg,25mg,100mg		EGFR	2 nM
A126830	AEE788 (NVP-AEE788)	≥97%	497839-62-0	5mg,25mg,100mg		HER2/ErbB2	6 nM
T126234	TAK-285	≥98%	871026-44-7	1mg,5mg,10mg,50mg		HER2	17 nM
T126234	TAK-285	≥98%	871026-44-7	1mg,5mg,10mg,50mg		EGFR(HER1)	23 nM
T129799	Tyrphostin AG 879	≥98%	148741-30-4	5mg,25mg,100mg	?	HER2/ErbB2	1 μM
N133726	去甲二氢愈创木酸	≥95%	500-38-9	1g,5g		IGF-1R/HER2
L193141	二甲苯磺酸拉帕替尼一水合物	0.98	388082-78-8	1g,5g		EGFR	10.8 nM
L193141	二甲苯磺酸拉帕替尼一水合物	0.98	388082-78-8	1g,5g		ErbB2	9.2 nM
E107404	(-)-表没食子儿茶素没食子酸	98%	989-51-5	100mg,200mg,2.5g	?	EGF/HER-2
E107403	(-)-表没食子儿茶素没食子酸	分析标准品	989-51-5	20mg,100mg		EGF/HER-2

*HIF

产品号	产品名称	规格	CAS	包装	细胞	靶点	IC50
M125960	2-Methoxyestradiol (2-MeOE2)	≥98%	362-07-2	10mg,25mg,50mg,100mg,500mg	?	?
P101691	芍药苷	≥98%(HPLC)	23180-57-6	10mg,500mg,5g	?
P101690	芍药苷	分析标准品,≥98%	23180-57-6	20mg
F126178	FG-4592	≥98%	808118-40-3	10mg,50mg,25mg	?	HIF-α脯氨酰羟化酶
I127127	IOX2	≥98%	931398-72-0	5mg,25mg,100mg	无细胞	PHD2	21 nM
V171541	Vadadustat	97%	1000025-07-9	100mg
N170064	N-acetylcysteine amide	98% (HPLC)	38520-57-9	5mg,25mg
D136754	DMOG	≥98% (HPLC)	89464-63-1	50mg,100mg,250mg,1g	?	HIF prolyl hydroxylase

*Bcr-Abl

项目号	产品名称	规格	CAS	包装	细胞	靶点	IC50	ED50
D125110	Dasatinib	≥99%	302962-49-8	25mg,100mg,500mg,1g,5g	无细胞	Abl	<1 nM
						Src	0.8 nM?
						c-Kit	79 nM
I129225	Imatinib Mesylate (STI571)	≥99%	220127-57-1	100mg,250mg,1g,5g,25g		v-Abl	0.6 μM
						c-Kit	0.1 μM
						PDGFR	0.1 μM
P127550	Ponatinib (AP24534)	≥99%	943319-70-8	10mg,50mg,250mg	无细胞	Abl	0.37 nM
						PDGFRα	1.1 nM
						VEGFR2	1.5 nM
						FGFR1	2.2 nM
						Src	5.4 nM
N126111	Nilotinib (AMN-107)	≥99%	641571-10-0	25mg,100mg,250mg,1g	小鼠骨髓祖细胞	BCR-ABL	＜30 nM
D126182	Danusertib (PHA-739358)	≥98%	827318-97-8	5mg,10mg,50mg	无细胞	Aurora A/B/C	13 nM/79 nM/61 nM
						Aurora A/B/C	13 nM/79 nM/61 nM
						Aurora A/B/C	13 nM/79 nM/61 nM
B129232	Bafetinib (INNO-406)	≥98%	859212-16-1	5mg,25mg,100mg	无细胞	Bcr-Abl	5.8 nM
B129232	Bafetinib (INNO-406)	≥98%	859212-16-1	5mg,25mg,100mg	无细胞	Lyn	19 nM
K127169	KW-2449	≥98%	1000669-72-6	5mg,25mg,100mg	?	Flt3	6.6 nM
N127928	NVP-BHG712	≥98%	940310-85-0	5mg,25mg,100mg		EphB4		25 nM
						c-Raf	0.395 μM
						c-Src	1.266 μM
						c-Abl	1.667 μM
P126419	PP121	≥98%	1092788-83-4	10mg,50mg		PDGFR	2 nM
						Hck	8 nM
						mTOR	10 nM
						VEGFR2	12 nM
						Src	14 nM
						Abl	18 nM
						DNA-PK	60 nM
D126373	DCC-2036 (Rebastinib)	≥99%	1020172-07-9	10mg,50mg		Abl1(WT)	0.8 nM
D126373	DCC-2036 (Rebastinib)	≥99%	1020172-07-9	10mg,50mg		Abl1(T315I)	4 nM
G129296	GZD824	≥99%	1421783-64-3	5mg,25mg		Bcr-Abl(WT)	0.34 nM
G129296	GZD824	≥99%	1421783-64-3	5mg,25mg		Bcr-Abl(T315I)	0.68 nM
G126166	GNF-2	≥98%	778270-11-4	5mg,25mg,50mg,250mg	?	Bcr-Abl
G177569	GNF-7	97%	839706-07-9	100mg		M351T	<5 nM
						T315I	61 nM
						E255 V	122 nM
						G250E	136 nM
						c-Abl	133 nM

*FAK

项目号	产品名称	规格	CAS	包装	细胞	靶点	IC50
P129811	PF-00562271	≥97%	939791-38-5	5mg,10mg,50mg	?	FAK	1.5 nM
P126147	PF-562271	≥98%	717907-75-0	5mg,10mg,50mg,100mg	?	FAK	1.5 nM
P129908	PRT062607 (P505-15, BIIB057) HCl	≥98%	1370261-97-4	5mg,25mg	无细胞	Syk	1 nM
P129814	PF-573228	≥98%	869288-64-2	10mg,50mg	无细胞	FAK	4 nM
T129808	TAE226 (NVP-TAE226)	≥99%	761437-28-9	5mg,10mg,50mg	?	FAK	5.5 nM
P127543	PF-03814735	≥99%	942487-16-3	1mg,5mg,10mg,50mg		Aurora A	0.8 nM
P127543	PF-03814735	≥99%	942487-16-3	1mg,5mg,10mg,50mg		Aurora B	0.5 nM
P126394	PND-1186	≥98%	1061353-68-1	5mg,25mg,100mg	?	FAK	1.5 nM
P127348	PF-431396	≥98%	717906-29-1	10mg,50mg		PYK2	11nM
P127348	PF-431396	≥98%	717906-29-1	10mg,50mg		FAK	2 nM

*ALK

项目号	产品名称	规格	CAS	包装	细胞	靶点	IC50	Ki
C137735	Crizotinib	≥99%	877399-52-5	10mg,50mg,100mg,250mg,500mg,1g,5g	无细胞	c-Met	11 nM
C137735	Crizotinib	≥99%	877399-52-5	10mg,50mg,100mg,250mg,500mg,1g,5g	无细胞	ALK	24 nM
T129819	TAE684 (NVP-TAE684)	≥98%	761439-42-3	5mg,10mg,50mg	无细胞	ALK	3 nM
C125242	CH5424802	≥98%	1256580-46-7	5mg,25mg,100mg	无细胞	ALK	1.9 nM
L127618	LDK378	≥99%	1032900-25-6	5mg,25mg,100mg,250mg	无细胞	ALK	0.2 nM
A127691	AP26113	≥98%	1197958-12-5	5mg,10mg,25mg,50mg,100mg		ALK
A127691	AP26113	≥98%	1197958-12-5	5mg,10mg,25mg,50mg,100mg		EGFR
A125664	AZD3463	≥98%	1356962-20-3	5mg,25mg,100mg	?	ALK		0.75 nM
A128022	ASP3026	≥98%	1097917-15-1	5mg,25mg,100mg	?	ALK?	3.5 nM
P167337	PF-06463922 acetate	98% (HPLC)	1454846-35-5	5mg		ROS1		<0.02 nM
						ALK (WT)		<0.07 nM
						ALK (L1196M)	?	0.7 nM

*FGFR

产品号	产品名称	规格	CAS	包装	细胞	靶点	IC50
S129593	Sorafenib Tosylate	≥99%	475207-59-1	10mg,50mg,250mg,1g,5g	无细胞	Raf-1	6 nM
					无细胞	B-Raf	22 nM
						VEGFR-2	90 nM
						VEGFR-3	20 nM
						PDGFR-β	57 nM
						Flt-3	59 nM
						c-KIT	68 nM
P127550	Ponatinib (AP24534)	≥99%	943319-70-8	10mg,50mg,250mg	无细胞	Abl	0.37 nM
						PDGFRα	1.1 nM
						VEGFR2	1.5 nM
						FGFR1	2.2 nM
						Src	5.4 nM
N127052	BGJ398 (NVP-BGJ398)	≥98%	872511-34-7	5mg,25mg,10mg	无细胞	FGFR1	0.9 nM
						FGFR2	1.4 nM
						FGFR3	1 nM
N129725	Nintedanib (BIBF 1120)	≥98%	656247-17-5	5mg,10mg,25mg,50mg,100mg,500mg	无细胞	VEGFR1	34 nM
						VEGFR2	13 nM
						VEGFR3	13 nM
						FGFR1	69 nM
						FGFR2	37 nM
						FGFR3	108 nM
						PDGFRα	59 nM
						PDGFRβ	65 nM
P129722	Pazopanib HCl (GW786034 HCl)	≥98%	635702-64-6	25mg,100mg,250mg,1g	无细胞	VEGFR1	10 nM
						VEGFR2	30 nM
						VEGFR3	47 nM
						PDGFR	84 nM
						FGFR	74 nM
						c-Kit	140 nM
						c-fms	146 nM
P125865	PD173074	≥99%	219580-11-7	5mg,10mg,50mg		FGFR1	25 nM
P125865	PD173074	≥99%	219580-11-7	5mg,10mg,50mg		VEGFR2	100-200 nM
D126778	Dovitinib (TKI-258, CHIR-258)	≥99%	405169-16-6	10mg,50mg,250mg	无细胞	FLT3	1 nM
D126778	Dovitinib (TKI-258, CHIR-258)	≥99%	405169-16-6	10mg,50mg,250mg	无细胞	c-Kit	2 nM
A127209	AZD4547	≥99%	1035270-39-3	5mg,10mg,25mg,50mg,100mg	无细胞	FGFR1	0.2 nM
						FGFR2	2.5 nM
						FGFR3	1.8 nM
D126182	Danusertib (PHA-739358)	≥98%	827318-97-8	1mg,5mg,10mg,50mg	无细胞	Aurora A	13 nM
						Aurora B	79 nM
						Aurora C	61 nM
L125518	Lenvatinib (E7080)	≥99%	417716-92-8	5mg,10mg,50mg,100mg	无细胞	VEGFR2/KDR?	4.0 nM
L125518	Lenvatinib (E7080)	≥99%	417716-92-8	5mg,10mg,50mg,100mg	无细胞	VEGFR3/FLT4	5.2 nM
B127317	Brivanib (BMS-540215)	≥98%	649735-46-6	5mg,10mg,50mg	?	VEGFR2	25 nM
E126318	ENMD-2076	≥99%	934353-76-1	5mg,10mg,50mg		Aurora A	14 nM
E126318	ENMD-2076	≥99%	934353-76-1	5mg,10mg,50mg		Flt3	1.86 nM
P125184	Pazopanib	≥99%	444731-52-6	25mg,100mg,500mg		GFR1	10 nM
						VEGFR2	30 nM
						VEGFR3	47 nM
						PDGFR	84 nM
						FGFR	74 nM
						c-Kit	140 nM
						c-Fms/CSF1R	146 nM
M129777	MK-2461	≥99%	917879-39-1	1mg,5mg,10mg,50mg	?	c-Met(WT/mutants)	0.4-2.5 nM
B129764	Brivanib Alaninate (BMS-582664)	≥95%	649735-63-7	10mg,50mg		VEGFR2	25 nM
T129775	Tyrphostin AG 1296	≥99%	146535-11-7	1mg,5mg,25mg		PDGFR	0.3-0.5 μM
					Swiss 3T3细胞	FGFR	12.3 μM
					Swiss 3T3细胞	c-Kit?	1.8 μM
L126507	LY2874455	≥99%	1254473-64-7	5mg,10mg,50mg		FGFR1	2.8 nM
						FGFR2	2.6 nM
						FGFR3	6.4 nM
						FGFR4	6 nM
						VEGFR2	7 nM
F103701	阿魏酸	99%	1135-24-6	5g,10g,25g,50g,100g,250g,500g,1kg	?	?
F103702	阿魏酸	分析标准品,≥99.5%（HPLC）	1135-24-6	20mg
O173545	ON-123300	97%	1357470-29-1	5mg,100mg		CDK4	3.9 nM
						Ark5/NUAK1	5 nM
						PDGFRβ	26 nM
						FGFR1	26 nM
						RET	9.2 nM
						Fyn	11nM
P132694	PD-166866	≥98%(HPLC)	192705-79-6	5mg,25mg,100mg	?	FGFR1	52.4 nM
B174512	BLU-9931	97%	1538604-68-0	5mg,100mg		FGFR4	3 nM